• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆蛋白质组学技术的技术评估

Technical Evaluation of Plasma Proteomics Technologies.

作者信息

Beimers William F, Overmyer Katherine A, Sinitcyn Pavel, Lancaster Noah M, Quarmby Scott T, Coon Joshua J

机构信息

Department of Biomolecular Chemistry, University of Wisconsin, Madison, Wisconsin 53506, United States.

Morgridge Institute for Research, Madison, Wisconsin 53515, United States.

出版信息

J Proteome Res. 2025 Jun 6;24(6):3074-3087. doi: 10.1021/acs.jproteome.5c00221. Epub 2025 May 14.

DOI:10.1021/acs.jproteome.5c00221
PMID:40366296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12150332/
Abstract

Plasma proteomics technologies are rapidly evolving and of critical importance to the field of biomedical research. Here, we report a technical evaluation of six notable plasma proteomics technologies─unenriched (Neat), acid depletion, PreOmics ENRICHplus, Mag-Net, Seer Proteograph XT, and Olink Explore HT. The methods were compared on proteomic depth, reproducibility, linearity, tolerance to lipid interference, and limit of detection/quantification. In total, we performed 618 LC-MS/MS experiments and 93 Olink Explore HT assays. The Seer method achieved the greatest proteomic depth (∼4500 proteins detected), while Olink detected ∼2600 proteins. Other MS-based methods ranged from ∼500-2200 proteins detected. In our analysis, Neat, Mag-Net, Seer, and Olink had good reproducibility, while PreOmics and Acid had higher variability (>20% median coefficient of variation). All MS methods showed good linearity with spiked-in C-reactive protein (CRP); CRP was surprisingly not in the Olink assay. None of the methods were affected by lipid interference. Seer produced the highest number of quantifiable proteins with a measurable LOD (4407) and LOQ (2696). Olink had the next highest number of quantifiable proteins, with 2002 having an LOD and 1883 having an LOQ. Finally, we tested the applicability of these methods for detecting differences between healthy and cancer groups in a nonsmall cell lung cancer (NSCLC) cohort. All six methods detected differentially abundant proteins between the cancer and healthy samples but disagreed on which proteins were significant, highlighting the contrast between each method.

摘要

血浆蛋白质组学技术正在迅速发展,对生物医学研究领域至关重要。在此,我们报告了对六种著名血浆蛋白质组学技术的技术评估——未富集(纯样)、酸去除、PreOmics ENRICHplus、Mag-Net、Seer Proteograph XT和Olink Explore HT。对这些方法在蛋白质组深度、重现性、线性、对脂质干扰的耐受性以及检测/定量限方面进行了比较。我们总共进行了618次液相色谱-串联质谱(LC-MS/MS)实验和93次Olink Explore HT分析。Seer方法实现了最大的蛋白质组深度(检测到约4500种蛋白质),而Olink检测到约2600种蛋白质。其他基于质谱的方法检测到的蛋白质数量在约500-2200种之间。在我们的分析中,纯样、Mag-Net、Seer和Olink具有良好的重现性,而PreOmics和酸去除法具有较高的变异性(中位变异系数>20%)。所有质谱方法与添加的C反应蛋白(CRP)均显示出良好的线性;令人惊讶的是,CRP不在Olink分析中。所有方法均未受脂质干扰的影响。Seer产生的可定量蛋白质数量最多,有可测量的检测限(LOD,4407)和定量限(LOQ,2696)。Olink的可定量蛋白质数量次之,有2002种具有检测限,1883种具有定量限。最后,我们测试了这些方法在非小细胞肺癌(NSCLC)队列中检测健康组和癌症组之间差异的适用性。所有六种方法均检测到癌症样本和健康样本之间存在差异丰富的蛋白质,但对于哪些蛋白质具有显著性存在分歧,凸显了每种方法之间的差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/31b7f0594876/pr5c00221_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/e3df82386e60/pr5c00221_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/6216811d2726/pr5c00221_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/574e922e2cce/pr5c00221_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/31b7f0594876/pr5c00221_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/e3df82386e60/pr5c00221_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/6216811d2726/pr5c00221_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/574e922e2cce/pr5c00221_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76b/12150332/31b7f0594876/pr5c00221_0004.jpg

相似文献

1
Technical Evaluation of Plasma Proteomics Technologies.血浆蛋白质组学技术的技术评估
J Proteome Res. 2025 Jun 6;24(6):3074-3087. doi: 10.1021/acs.jproteome.5c00221. Epub 2025 May 14.
2
A Technical Evaluation of Plasma Proteomics Technologies.血浆蛋白质组学技术的技术评估
bioRxiv. 2025 Jan 13:2025.01.08.632035. doi: 10.1101/2025.01.08.632035.
3
i-RUBY: a novel software for quantitative analysis of highly accurate shotgun-proteomics liquid chromatography/tandem mass spectrometry data obtained without stable-isotope labeling of proteins.i-RUBY:一种新型软件,用于对未进行蛋白质稳定同位素标记的高精准性 shotgun 蛋白质组学液相色谱/串联质谱获得的数据进行定量分析。
Rapid Commun Mass Spectrom. 2011 Apr 15;25(7):960-8. doi: 10.1002/rcm.4943. Epub 2011 Mar 14.
4
LC-MS/MS-based quantification of efflux transporter proteins at the BBB.基于 LC-MS/MS 的 BBB 外排转运蛋白定量分析。
J Pharm Biomed Anal. 2019 Feb 5;164:496-508. doi: 10.1016/j.jpba.2018.11.013. Epub 2018 Nov 8.
5
timsTOF HT Improves Protein Identification and Quantitative Reproducibility for Deep Unbiased Plasma Protein Biomarker Discovery.timsTOF HT 提高了蛋白质鉴定和定量重现性,有助于深入、无偏的血浆蛋白质生物标志物发现。
J Proteome Res. 2024 Mar 1;23(3):929-938. doi: 10.1021/acs.jproteome.3c00646. Epub 2024 Jan 15.
6
Exploration of differentially expressed plasma proteins in patients with lung adenocarcinoma using iTRAQ-coupled 2D LC-MS/MS.使用iTRAQ偶联二维液相色谱-串联质谱法探索肺腺癌患者血浆中差异表达的蛋白质
Clin Respir J. 2018 Jun;12(6):2036-2045. doi: 10.1111/crj.12771. Epub 2018 Feb 21.
7
A Combination of DNA-peptide Probes and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): A Quasi-Targeted Proteomics Approach for Multiplexed MicroRNA Quantification.DNA肽探针与液相色谱-串联质谱联用(LC-MS/MS):一种用于多重微小RNA定量的准靶向蛋白质组学方法。
Theranostics. 2017 Jul 8;7(11):2849-2862. doi: 10.7150/thno.19113. eCollection 2017.
8
A comparative analysis of human plasma and serum proteins by combining native PAGE, whole-gel slicing and quantitative LC-MS/MS: Utilizing native MS-electropherograms in proteomic analysis for discovering structure and interaction-correlated differences.结合非变性聚丙烯酰胺凝胶电泳、全凝胶切片和定量液相色谱-串联质谱法对人血浆和血清蛋白进行比较分析:在蛋白质组学分析中利用非变性质谱电泳图发现结构和相互作用相关差异。
Electrophoresis. 2017 Dec;38(24):3111-3123. doi: 10.1002/elps.201700261. Epub 2017 Sep 26.
9
An off-line high pH reversed-phase fractionation and nano-liquid chromatography-mass spectrometry method for global proteomic profiling of cell lines.一种用于细胞系整体蛋白质组分析的离线高pH反相分级分离和纳升液相色谱-质谱联用方法。
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 1;974:90-5. doi: 10.1016/j.jchromb.2014.10.031. Epub 2014 Nov 4.
10
Multiplatform Approach for Plasma Proteomics: Complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein Profiling.多平台血浆蛋白质组学方法:Olink 邻近延伸分析技术与基于质谱的蛋白质分析的互补性。
J Proteome Res. 2021 Jan 1;20(1):751-762. doi: 10.1021/acs.jproteome.0c00641. Epub 2020 Nov 30.

引用本文的文献

1
Multiplexed Quantification of First-Trimester Serum Biomarkers in Healthy Pregnancy.健康妊娠早期血清生物标志物的多重定量分析
Int J Mol Sci. 2025 Aug 18;26(16):7970. doi: 10.3390/ijms26167970.
2
High-throughput plasma/serum proteomics by coupling nanoparticle protein corona-based sample preparation and capillary zone electrophoresis-tandem mass spectrometry.通过结合基于纳米颗粒蛋白冠的样品制备和毛细管区带电泳-串联质谱法进行高通量血浆/血清蛋白质组学研究。
Anal Methods. 2025 Jul 29. doi: 10.1039/d5ay00721f.
3
Thin-diaPASEF: diaPASEF for maximizing proteome coverage in single-shot proteomics.

本文引用的文献

1
Small molecule modulation of protein corona for deep plasma proteome profiling.小分子调控蛋白冠用于深度血浆蛋白质组分析。
Nat Commun. 2024 Nov 7;15(1):9638. doi: 10.1038/s41467-024-53966-z.
2
Fast and deep phosphoproteome analysis with the Orbitrap Astral mass spectrometer.利用 Orbitrap Astral 质谱仪进行快速而深入的磷酸化蛋白质组分析。
Nat Commun. 2024 Aug 15;15(1):7016. doi: 10.1038/s41467-024-51274-0.
3
Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes.
薄直径PASEF:用于在单次蛋白质组学中最大化蛋白质组覆盖范围的直径PASEF。
DNA Res. 2025 Jul 4;32(4). doi: 10.1093/dnares/dsaf019.
4
Large-scale evaluation of proteomic and polygenic risk scores reveals complementary contributions to incident disease prediction.蛋白质组学和多基因风险评分的大规模评估揭示了对疾病发病预测的互补作用。
medRxiv. 2025 Jul 11:2025.07.10.25331242. doi: 10.1101/2025.07.10.25331242.
5
The evolution of analytical techniques for multiplex analysis of protein biomarkers.用于蛋白质生物标志物多重分析的分析技术的演变
Expert Rev Proteomics. 2025 Jul;22(7):255-272. doi: 10.1080/14789450.2025.2529185. Epub 2025 Jul 10.
6
The Need for Better Validation: Evaluating Aptamer and Proximity Extension Assays for Large-Scale Clinical Proteomics Studies.更好验证的必要性:评估适体和邻近延伸分析用于大规模临床蛋白质组学研究
Clin Chem. 2025 Apr 24. doi: 10.1093/clinchem/hvaf046.
对 1117 名住院 COVID-19 患者的纵向血浆蛋白质组学分析鉴定出与严重程度和结局相关的特征。
Sci Adv. 2024 May 24;10(21):eadl5762. doi: 10.1126/sciadv.adl5762.
4
Optimizing differential expression analysis for proteomics data via high-performing rules and ensemble inference.通过高性能规则和集成推理优化蛋白质组学数据的差异表达分析。
Nat Commun. 2024 May 9;15(1):3922. doi: 10.1038/s41467-024-47899-w.
5
The One Hour Human Proteome.人类蛋白质组一小时绘制完成
Mol Cell Proteomics. 2024 May;23(5):100760. doi: 10.1016/j.mcpro.2024.100760. Epub 2024 Apr 3.
6
timsTOF HT Improves Protein Identification and Quantitative Reproducibility for Deep Unbiased Plasma Protein Biomarker Discovery.timsTOF HT 提高了蛋白质鉴定和定量重现性,有助于深入、无偏的血浆蛋白质生物标志物发现。
J Proteome Res. 2024 Mar 1;23(3):929-938. doi: 10.1021/acs.jproteome.3c00646. Epub 2024 Jan 15.
7
Organ aging signatures in the plasma proteome track health and disease.血浆蛋白质组中的器官衰老特征可跟踪健康和疾病。
Nature. 2023 Dec;624(7990):164-172. doi: 10.1038/s41586-023-06802-1. Epub 2023 Dec 6.
8
Plasma proteomic associations with genetics and health in the UK Biobank.英国生物库中血浆蛋白质组与遗传学和健康的关联。
Nature. 2023 Oct;622(7982):329-338. doi: 10.1038/s41586-023-06592-6. Epub 2023 Oct 4.
9
Evaluating the Performance of the Astral Mass Analyzer for Quantitative Proteomics Using Data-Independent Acquisition.使用数据非依赖采集方法评估 Astral 质量分析仪在定量蛋白质组学中的性能。
J Proteome Res. 2023 Oct 6;22(10):3290-3300. doi: 10.1021/acs.jproteome.3c00357. Epub 2023 Sep 8.
10
A simple, time- and cost-effective, high-throughput depletion strategy for deep plasma proteomics.一种简单、经济高效、高通量的深血浆蛋白质组学耗竭策略。
Sci Adv. 2023 Mar 29;9(13):eadf9717. doi: 10.1126/sciadv.adf9717.